Fresenius To Market Cypress Bioscience's Prosorba For Rheumatoid Arthritis
This article was originally published in The Gray Sheet
Executive Summary
Cypress Bioscience is hoping to gain broad market exposure for its Prosorba column in the treatment of rheumatoid arthritis through a distribution agreement with the German firm Fresenius AG and its U.S. subsidiary Fresenius Hemotechnology Inc.